Reply: Is high-dose glucocorticoid beneficial in COVID-19?

Maryam Edalatifard; Maryam Akhtari; Mohammadreza Salehi; Elham Farhadi; Ahmadreza Jamshidi; Mahdi Mahmoudi; Abdolrahman Rostamian

doi:10.1183/13993003.00324-2021

Reply: Is high-dose glucocorticoid beneficial in COVID-19?

Eur Respir J. 2021 Apr 15;57(4):2100324. doi: 10.1183/13993003.00324-2021. Print 2021 Apr.

Authors

Maryam Edalatifard¹, Maryam Akhtari^{2

3}, Mohammadreza Salehi⁴, Elham Farhadi^{2

3}, Ahmadreza Jamshidi², Mahdi Mahmoudi^{2

3}, Abdolrahman Rostamian⁵

Affiliations

¹ Advanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran.
² Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
³ Inflammation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Dept of Infectious and Tropical Medicines, Tehran University of Medical Sciences, Tehran, Iran.
⁵ Rheumatology Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran [email protected].

Abstract

Our clinical trial supports the beneficial use of a high dose of methylprednisolone for the treatment of severe COVID-19 patients. https://bit.ly/3qvc4Kz

Publication types

Letter
Comment

MeSH terms

COVID-19*
Glucocorticoids*
Humans
Methylprednisolone
SARS-CoV-2

Substances

Glucocorticoids
Methylprednisolone